Tirzepatide in NASH and Cirrhosis

Safety and Efficacy

• The American Diabetes Association states that insulin is preferred for decompensated cirrhosis due to lack of robust safety data for GLP-1/GIP agonists 1, 5
• GLP-1 receptor agonists are contraindicated in Child-Pugh C cirrhosis 2
• Tirzepatide may be used with caution in compensated cirrhosis (Child-Pugh A), but long-term safety data are lacking 1, 3, 4
• Pioglitazone is contraindicated in decompensated cirrhosis 3, 4

Comparison to Alternative Therapies

• Semaglutide achieved 59% NASH resolution at 0.4 mg daily versus 17% placebo 1, 7
• Pioglitazone improves NASH resolution (47% vs 21% placebo) and may reverse advanced fibrosis 8, 3, 4
• SGLT2 inhibitors reduce hepatic steatosis by approximately 20% on imaging 3, 4

Clinical Implementation

• Monitor liver function tests (ALT, AST, bilirubin, albumin) every 4-8 weeks initially in compensated cirrhosis 5
• Ensure adequate protein intake (1.2-1.5 g/kg/day) to prevent sarcopenia during weight loss 5
• Have a low threshold to switch to insulin if any signs of decompensation emerge in compensated cirrhosis 1, 5